Earnest Partners LLC Has $141.69 Million Stock Holdings in Icon Plc $ICLR

Earnest Partners LLC lifted its position in shares of Icon Plc (NASDAQ:ICLR) by 36.2% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 809,652 shares of the medical research company’s stock after buying an additional 215,355 shares during the quarter. Earnest Partners LLC’s holdings in Icon were worth $141,689,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Artisan Partners Limited Partnership boosted its position in Icon by 67.4% during the 2nd quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company’s stock worth $1,045,039,000 after buying an additional 2,893,946 shares during the period. Principal Financial Group Inc. increased its position in Icon by 739.2% in the 3rd quarter. Principal Financial Group Inc. now owns 3,277,293 shares of the medical research company’s stock valued at $573,526,000 after acquiring an additional 2,886,755 shares during the period. Harris Associates L P acquired a new position in Icon in the 2nd quarter valued at approximately $238,256,000. Norges Bank bought a new position in shares of Icon during the second quarter valued at $158,639,000. Finally, 1832 Asset Management L.P. lifted its holdings in shares of Icon by 587.9% during the second quarter. 1832 Asset Management L.P. now owns 1,151,328 shares of the medical research company’s stock worth $167,461,000 after purchasing an additional 983,950 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

Icon Price Performance

ICLR stock opened at $98.33 on Friday. The firm has a market cap of $7.94 billion, a price-to-earnings ratio of 13.31, a PEG ratio of 2.52 and a beta of 1.35. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon Plc has a 12-month low of $66.57 and a 12-month high of $211.00. The company’s fifty day simple moving average is $144.09 and its 200 day simple moving average is $165.46.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ICLR shares. Weiss Ratings reissued a “hold (c)” rating on shares of Icon in a research note on Monday, December 29th. Mizuho set a $216.00 target price on Icon in a report on Friday, January 9th. Barclays reduced their price target on Icon from $200.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Monday, March 9th. BMO Capital Markets reissued a “market perform” rating and issued a $100.00 price target on shares of Icon in a research note on Thursday, February 12th. Finally, Robert W. Baird set a $119.00 price objective on Icon in a research report on Friday, February 13th. Six investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $146.80.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.